BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties

  • Authors:
    • Michio Nishida
    • Norio Uematsu
    • Hideaki Kobayashi
    • Yuka Matsunaga
    • Shoko Ishida
    • Minoru Takata
    • Ohtsura Niwa
    • Eduardo A. Padlan
    • Roland Newman
  • View Affiliations

  • Published online on: December 6, 2010     https://doi.org/10.3892/ijo.2010.864
  • Pages: 335-344
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rituximab (chimeric anti-CD20 mAb) is currently used in the treatment of B-NHL and B cell malignancies, alone or in combination with chemotherapy. However, subsets of patients do not initially respond and/or develop resistance to additional treatments. Hence, there is a need to develop more effective anti-CD20 mAbs that may improve clinical response. BM-ca is a novel humanized anti-CD20 mAb that was tested against several B-NHL cell lines and was compared to several anti-CD20 mAbs (Rituximab, ofatumumab, 2H7, B1 and B-Ly1). BM-ca was shown to strongly induce both homotypic cell aggregation and redistribution of CD20 to membrane lipid rafts. BM-ca was also able to induce programmed cell death (apoptosis) without the need for cross-linking and demonstrated potent complement-dependent cytotoxicity (CDC). BM-ca was more cytotoxic than rituximab even in malignant B cells expressing low amounts of membrane CD20. Type I anti-CD20 mAbs typically induce minimal levels of homotypic cell aggregation and apoptosis but strong localization of CD20 to lipid rafts and potent CDC. Type II anti-CD20 mAbs typically exert the reverse activities. Noteworthy, BM-ca exhibits properties that are shared by both type I and type II anti-CD20 mAbs, which may reflect the recognition of a new CD20 epitope and/or exhibit different molecular signaling. Overall, the present data show that BM-ca is a novel anti-CD20 mAb that may be classified as a type I/II. The therapeutics efficacy of BM-ca awaits its use in clinical trials.

Related Articles

Journal Cover

February 2011
Volume 38 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nishida M, Uematsu N, Kobayashi H, Matsunaga Y, Ishida S, Takata M, Niwa O, Padlan EA and Newman R: BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol 38: 335-344, 2011
APA
Nishida, M., Uematsu, N., Kobayashi, H., Matsunaga, Y., Ishida, S., Takata, M. ... Newman, R. (2011). BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. International Journal of Oncology, 38, 335-344. https://doi.org/10.3892/ijo.2010.864
MLA
Nishida, M., Uematsu, N., Kobayashi, H., Matsunaga, Y., Ishida, S., Takata, M., Niwa, O., Padlan, E. A., Newman, R."BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties". International Journal of Oncology 38.2 (2011): 335-344.
Chicago
Nishida, M., Uematsu, N., Kobayashi, H., Matsunaga, Y., Ishida, S., Takata, M., Niwa, O., Padlan, E. A., Newman, R."BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties". International Journal of Oncology 38, no. 2 (2011): 335-344. https://doi.org/10.3892/ijo.2010.864